| Code | CSB-RA004929MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Erzotabart, targeting CD38, a type II transmembrane glycoprotein with multiple enzymatic functions. CD38 acts as both an ectoenzyme regulating NAD+ metabolism and a receptor involved in cell adhesion and signal transduction. It catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, a critical second messenger in calcium signaling pathways. CD38 is highly expressed on various immune cells and shows particularly elevated expression on malignant plasma cells in multiple myeloma, making it a valuable marker and therapeutic target in hematological malignancies.
Erzotabart is an IgG1-kappa, anti-CD38 humanized monoclonal antibody. Erzotabart promotes the formation of antibody hexamers through the E430G mutation in the Fc fragment and exhibits immunomodulatory and anti-tumor activities. Erzotabart induces complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), phagocytosis, inhibits CD38 cyclase activity, and increases hydrolase activity. This biosimilar provides researchers with a valuable tool for investigating CD38-mediated pathways, studying immune cell function, and exploring therapeutic mechanisms in oncology and immunology research. It supports investigations into plasma cell disorders, autoimmune diseases, and cellular metabolism studies involving NAD+ signaling.
There are currently no reviews for this product.